Immunai logo

Immunai Funding & Investors

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

immunai.com

Total Amount Raised: $295,000,000

Immunai Funding Rounds

  • Series B

    $215,000,000

    Series B Investors

    Koch Disruptive Technologies
    Talos VC
    8VC
    Alexandria Venture Investments
    Piedmont Capital Investments
    Meron Capital
    ICon
  • Series B

    $215,000,000

    Series B Investors

    Koch Disruptive Technologies
    Talos VC
    8VC
    Alexandria Venture Investments
    Piedmont Capital Investments
    Meron Capital
    ICon
  • Series A

    $60,000,000

    Series A Investors

    Catalio Capital Management
    Charles and Lynn Schusterman Family Philanthropies
    Dexcel Pharma
    Duquesne Family Office
    TLV Partners
    Viola Group
    Meron Capital
  • Seed

    $20,000,000

    Seed Investors

    TLV Partners
    Viola Group
    Meron Capital
    Gefen Capital
  • Series A

    $60,000,000

    Series A Investors

    Catalio Capital Management
    Charles and Lynn Schusterman Family Philanthropies
    Dexcel Pharma
    Duquesne Family Office
    TLV Partners
    Viola Group
    Meron Capital
  • Seed

    $20,000,000

    Seed Investors

    TLV Partners
    Viola Group
    Meron Capital
    Gefen Capital
Funding info provided by Diffbot.